NCT07359963
Not yet recruiting
Early Phase 1
An Exploratory Clinical Study on the Intravenous Infusion of REGEND007 (Generic Airway Basal Layer Stem Cell Preparation) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Regend Therapeutics0 sites12 target enrollmentStarted: February 15, 2026Last updated:
Overview
- Phase
- Early Phase 1
- Status
- Not yet recruiting
- Sponsor
- Regend Therapeutics
- Enrollment
- 12
Overview
Brief Summary
This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Gender is not restricted. When signing the informed consent form, the age should be between 40 and 80 years old (inclusive of the boundary value).
- •Diagnosed with idiopathic pulmonary fibrosis (IPF).
- •During the screening process, the six-minute walk test should be ≥ 150 meters and \< 600 meters; or the lung function FVC should be \> 30% of the predicted value.
- •Voluntarily sign the informed consent form, be able to cooperate with the completion of research-related procedures and examinations, and be able to comprehensively describe or record the changes in the condition.
Exclusion Criteria
- •Female subjects who are pregnant, breastfeeding, or planning to become pregnant within one year after using this product; or male subjects whose partner is planning to become pregnant.
- •Subjects selected during the screening whose estimated survival period is less than one year.
- •Subjects selected during the screening who have a current or past history of malignant tumors (excluding malignant tumors with a disease-free survival of more than five years and judged by the researcher to have a relatively mild invasiveness, such as non-melanoma skin cancer, invasive cervical cancer, bladder cancer, thyroid cancer, and breast cancer, etc.).
- •Subjects selected within 4 weeks before diagnosis of pneumonia (including bacterial, fungal or viral pneumonia).
- •Subjects selected within 4 weeks before an acute exacerbation of IPF.
- •Subjects selected within 4 weeks before having one or more results reported by pathogenological or serological tests (nucleic acid, antigen, virus culture, specific IgG antibody levels) indicating novel coronavirus infection, or suspected novel coronavirus infection (manifesting symptoms such as fever, headache, fatigue, joint pain, runny nose, sore throat, and persistent cough, and the disease course is consistent with the prevalent strain).
- •Subjects selected within 4 weeks before having a history of invasive or non-invasive mechanical ventilation.
- •Subjects selected during the screening who have active pulmonary tuberculosis, poorly controlled bronchial asthma, acute pulmonary embolism, severe pulmonary hypertension \[cardiac ultrasound examination \> 70 mmHg\], etc.
- •Subjects selected within 6 months before having a serious non-pulmonary systemic disease and judged by the researcher as not suitable to participate in this study, such as diabetes with ketoacidosis or hyperosmolar coma, acute myocardial infarction, unstable angina pectoris, NYHA heart failure grade III/IV, stroke, liver cirrhosis with severe liver dysfunction, severe renal insufficiency, etc.
- •Subjects selected during the screening who have severe anemia, or controlled poorly granulocytopenia or thrombocytopenia.
Investigators
Similar Trials
Not yet recruiting
Phase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult SubjectsNCT07345364Jiangsu Simcere Pharmaceutical Co., Ltd.56
Recruiting
Phase 4
Determination of the Effective Dose of a Single Intravenous Dose of Tegileridine Fumarate for Postoperative Analgesia After Orthopedic Surgery: A Up-and-Down Sequential Allocation StudyNCT07353996Second Affiliated Hospital, School of Medicine, Zhejiang University180
Recruiting
Early Phase 1
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCNCT07355972Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune DiseasesNCT07333118Grit Biotechnology22
Recruiting
Early Phase 1
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus ErythematosusNCT07339332Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12